Since PD-L1 is mainly expressed on the surface of tumor cells, anti-PD-L1-based bsAbs may recruit various therapeutic immune cells in TME and exerts synergistic antitumor effects, thus opening a new window for cancer immunotherapy. This evidence concerns the gene CD274 and neoplasm.